Next Article in Journal
Emerging Trends for Radio-Immunotherapy in Rectal Cancer
Next Article in Special Issue
Detecting and Characterizing A-To-I microRNA Editing in Cancer
Previous Article in Journal
Serum Exosomes and Their miRNA Load—A Potential Biomarker of Lung Cancer
Previous Article in Special Issue
miRNA Expression Signatures of Therapy Response in Squamous Cell Carcinomas

Non-Coding RNAs in Cancer Diagnosis and Therapy: Focus on Lung Cancer

Division of Pulmonary Diseases and Critical Care Medicine, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA 23298, USA
Author to whom correspondence should be addressed.
Academic Editor: Triantafillos Liloglou
Cancers 2021, 13(6), 1372;
Received: 11 February 2021 / Revised: 3 March 2021 / Accepted: 11 March 2021 / Published: 18 March 2021
(This article belongs to the Special Issue Nucleic Acids in Cancer Diagnosis and Therapy)
Researchers have spent nearly two decades unraveling the roles of non-coding RNAs in cancer biology. In recent years, deep transcriptomic profiling of tissue and circulating non-coding RNAs in cancer patients have elucidated non-coding RNAs as potential biomarkers that can inform cancer diagnosis and prognosis. Clinical trials have also begun examining non-coding RNA-based drugs as adjuncts to traditional chemotherapeutics. Overall, our review is structured to provide an overview of non-coding RNAs in cancer biology, diagnostics, and therapeutics, focusing on lung cancer.
Over the last several decades, clinical evaluation and treatment of lung cancers have largely improved with the classification of genetic drivers of the disease, such as EGFR, ALK, and ROS1. There are numerous regulatory factors that exert cellular control over key oncogenic pathways involved in lung cancers. In particular, non-coding RNAs (ncRNAs) have a diversity of regulatory roles in lung cancers such that they have been shown to be involved in inducing proliferation, suppressing apoptotic pathways, increasing metastatic potential of cancer cells, and acquiring drug resistance. The dysregulation of various ncRNAs in human cancers has prompted preclinical studies examining the therapeutic potential of restoring and/or inhibiting these ncRNAs. Furthermore, ncRNAs demonstrate tissue-specific expression in addition to high stability within biological fluids. This makes them excellent candidates as cancer biomarkers. This review aims to discuss the relevance of ncRNAs in cancer pathology, diagnosis, and therapy, with a focus on lung cancer. View Full-Text
Keywords: non-coding RNA; lung cancer; cancer diagnosis; cancer therapy non-coding RNA; lung cancer; cancer diagnosis; cancer therapy
Show Figures

Figure 1

MDPI and ACS Style

Le, P.; Romano, G.; Nana-Sinkam, P.; Acunzo, M. Non-Coding RNAs in Cancer Diagnosis and Therapy: Focus on Lung Cancer. Cancers 2021, 13, 1372.

AMA Style

Le P, Romano G, Nana-Sinkam P, Acunzo M. Non-Coding RNAs in Cancer Diagnosis and Therapy: Focus on Lung Cancer. Cancers. 2021; 13(6):1372.

Chicago/Turabian Style

Le, Patricia; Romano, Giulia; Nana-Sinkam, Patrick; Acunzo, Mario. 2021. "Non-Coding RNAs in Cancer Diagnosis and Therapy: Focus on Lung Cancer" Cancers 13, no. 6: 1372.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop